<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387501</url>
  </required_header>
  <id_info>
    <org_study_id>APTE</org_study_id>
    <nct_id>NCT03387501</nct_id>
  </id_info>
  <brief_title>Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium</brief_title>
  <acronym>APTE</acronym>
  <official_title>Efficacy and Safety of the Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium in Patients Undergoing Transfer of Cryo-preserved Embryos: Clinical Trial II.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Rafael Fernandez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the percentage of women with thin endometrium who achieve an endometrial
      thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth
      factors)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of women who achieve an endometrial thickness equal to or greater than 7 mm</measure>
    <time_frame>3 days after administration of PRGF</time_frame>
    <description>Measurement of the endometrial thickness by ultrasonography.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Infertility</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>PRGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma rich in growth factors (PRGF) administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma rich in growth factors (PRGF-Endoret)</intervention_name>
    <description>Intrauterine administration of PRGF</description>
    <arm_group_label>PRGF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who signed informed consent.

          -  Women who understand the Spanish language.

          -  Women under 40 years

        Exclusion Criteria:

          -  Thrombopenia.

          -  Congenital or acquired uterine malformations that reduce embryo implantation or term
             gestation.

          -  Ovarian tumors.

          -  Benign uterine tumors require surgical treatment

          -  Local acute inflammatory diseases

          -  Patients with malignant tumors requiring chemotherapy.

          -  Patients with acute or chronic infectious or inflammatory diseases requiring active
             treatment with drugs that may interfere with implantation and gestation.

          -  Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Rafael, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico San Carlos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Rafael Fernandez</last_name>
    <phone>+34 913303000</phone>
    <phone_ext>3766</phone_ext>
    <email>sara.rafael@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Rafael, PhD</last_name>
      <phone>+34913303000</phone>
      <email>sara.rafael@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Sara Rafael Fernandez</investigator_full_name>
    <investigator_title>Head of Assisted Reproduction Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

